Project Grant R01HD121129
- The National Institute of Child Health and Human Development awarded the University of Washington $383,200 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to optimize transcutaneous spinal cord stimulation intensity for gait training in children with cerebral palsy. The research systematically evaluates how varying spinal stimulation intensities affect gait biomechanics in ambulatory children with bilateral cerebral palsy. In the first aim,...
- The National Institute of Child Health and Human Development awarded the University of Washington $647,235 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to evaluate a developmental powered mobility intervention for young children with cerebral palsy. The award funds a randomized clinical trial of the Developmental Power Mobility (DPM) intervention, which leverages an FDA-cleared Explorer Mini device to address mobility limitations in...
- The National Institute of Child Health and Human Development awarded The Children's Hospital of Philadelphia $482,901 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop precise measurement approaches for selective motor control impairment in children with cerebral palsy. The research characterizes patterns of impaired motor control in cerebral palsy using electromyography paired with biofeedback during single-joint movement...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded $150,342 to the University of Washington on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds investigation of how long-term, closed-loop, epidural spinal cord stimulation affects neuropathic pain symptoms in rats with cervical spinal cord injury. The...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Washington $212,265 on August 21, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a closed-loop system for personalizing transcutaneous spinal stimulation (TSCS) amplitude during locomotor rehabilitation for individuals with neurological impairments from spinal cord injury, stroke, multiple sclerosis, traumatic brain...
- The National Institute of Child Health and Human Development awarded Kessler Foundation, Inc. $562,228 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a project grant investigating transcutaneous spinal cord stimulation for blood pressure regulation and orthostatic hypotension in individuals with spinal cord injury. The study will recruit ten individuals at least one year post-spinal cord injury with orthostatic hypotension and...
- The National Institute of Neurological Disorders and Stroke awarded Drexel University $149,190 on July 14, 2026, under CFDA 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders) to conduct research on transcutaneous spinal cord stimulation and its mechanisms for reducing spasticity following spinal cord injury. The research investigates whether transcutaneous spinal cord stimulation improves spasticity after spinal cord injury by upregulating KCC2, a chloride...
- The National Institute of Child Health and Human Development awarded Washington University $667,506 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop a caregiver-reported dystonia impact scale for children with cerebral palsy. The project addresses underdiagnosis of dystonia in cerebral palsy, a condition affecting 1 in 500 people in the United States. Dystonia commonly causes motor functional limitations in childhood but is...
- The National Institute of Child Health and Human Development awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $431,781 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate the impacts of genetic testing in individuals with cerebral palsy. The project will examine family perspectives on the psychosocial impact and utility of genetic testing for cerebral palsy, assess whether a genetic...
- The National Institute of Child Health and Human Development awarded The Regents of the University of California, San Francisco $638,608 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a randomized controlled trial evaluating functional electrical stimulation (FES) for improving gait mobility and real-world outcomes in people with multiple sclerosis who have foot drop. The study design encompasses a four-month RCT with 70...
The National Institute of Child Health and Human Development awarded the University of Washington $616,250 on September 1, 2026, through the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a randomized controlled trial evaluating non-invasive spinal cord stimulation combined with intensive treadmill training to reduce spasticity and improve mobility in children with cerebral palsy. The research will enroll children with cerebral palsy in a 24-session protocol (three sessions per week for eight weeks) comparing outcomes with and without transcutaneous spinal cord stimulation applied over the lumbar spine. The stimulation targets primary sensory afferents to reduce spasticity. Investigators will measure changes in spasticity and gait using quantitative gait analysis and wearable sensors to monitor community walking, with follow-up assessments extending six months beyond the intervention period. The study will also capture the lived experiences of children and caregivers through semi-structured interviews to understand how the intervention supports mobility and participation goals. The award addresses an urgent clinical need for non-invasive alternatives to invasive procedures such as selective dorsal rhizotomy or medications like baclofen, which carry substantial side effects and require prolonged rehabilitation. Performance occurs in Seattle, Washington. The period of performance extends from September 1, 2026, through August 31, 2031. The University of Washington's Office of Sponsored Programs administers the award as prime recipient.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $616.3k | 8/31/26 |